Neil Exter

Neil Exter brings more than two decades of experience in biotech business development and strategy. A partner at Third Rock Ventures, he has served in key leadership roles at more than a dozen portfolio companies, including Bluebird Bio, Goldfinch Bio and Revolution Medicines. Before joining Third Rock in 2007, Neil was chief business officer of Alantos Pharmaceuticals and led the sale of the company to Amgen. He also served as vice president at Millennium Pharmaceuticals, directing in-licensing and M&A. Neil holds an MBA from Harvard Business School and a master’s degree from Stanford University.